

Ron D Jachimowicz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9636003/publications.pdf>

Version: 2024-02-01

16
papers

375
citations

1040056

9
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

758
citing authors

#	ARTICLE	IF	CITATIONS
1	Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. <i>Infection</i> , 2022, 50, 1399-1404.	4.7	20
2	Correspondence to: hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. <i>Infection</i> , 2022, , 1.	4.7	4
3	Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer. <i>Breast Cancer Research</i> , 2022, 24, .	5.0	5
4	Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma. <i>Molecular Oncology</i> , 2021, 15, 1069-1087.	4.6	14
5	Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP. <i>Leukemia</i> , 2021, 35, 3589-3593.	7.2	8
6	Abstract LB218: MRE11A expression regulated by UBQLN4 is related to cisplatin-resistance and survival in patients with esophageal squamous cell carcinoma. , 2021, , .		0
7	Biallelic variants in YRDC cause a developmental disorder with progeroid features. <i>Human Genetics</i> , 2021, 140, 1679-1693.	3.8	3
8	Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma. <i>Cells</i> , 2020, 9, 2287.	4.1	9
9	DNA double-strand break repair pathway choice - from basic biology to clinical exploitation. <i>Cell Cycle</i> , 2019, 18, 1423-1434.	2.6	20
10	UBQLN4 promotes non-homologous end joining by repressing DNA end-resection. <i>Molecular and Cellular Oncology</i> , 2019, 6, 1-3.	0.7	6
11	UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. <i>Cell</i> , 2019, 176, 505-519.e22.	28.9	100
12	The Challenging Aspects of Managing Adolescents and Young Adults with Hodgkin's Lymphoma. <i>Acta Haematologica</i> , 2014, 132, 274-278.	1.4	11
13	The bispecific immunoligand ULBP2â€œCEA redirects natural killer cells to tumor cells and reveals potent antiâ€œtumor activity against colon carcinoma. <i>International Journal of Cancer</i> , 2014, 134, 2829-2840.	5.1	50
14	Multi-Specific Antibodies for Cancer Immunotherapy. <i>BioDrugs</i> , 2014, 28, 331-343.	4.6	17
15	Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 113-115.	4.1	77
16	Induction of <i>In Vitro</i> and <i>In Vivo</i> NK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Prostate-Specific Membrane Antigen in Prostate Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1036-1045.	4.1	31